Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The effect of gene knockdown in anthracycline induced cardiotoxicity in human induced pluripotent stem cell derived cardiomyocytes
EF 2018-19
Résumé
Anthracyclines, a chemotherapeutic agent, play an important role in improving the survival rates of a wide range of childhood cancers. Despite the importance of anthracyclines in cancer treatments, their use is complicated by the development of heart-related toxicities (known as cardiotoxicities) that have the potential of resulting in heart failure. While there are a variety of known risk factors (e.g. age of diagnosis and dose of drug) implicated in anthracycline-induced cardiotoxicity, it is difficult to accurately determine who is most at risk. Therefore there is a major need to better predict and identify the patients at the highest risk for cardiotoxicity. Recently, variations in genes have been explored as more accurate predictors of a susceptibility to cardiotoxicity. However, there is a limited understanding of how these genetic variations affect cardiomyocytes, primary cells of the heart. In order to address this, I will model cardiotoxicity using human stem cell-derived cardiomyocytes in order to study the effect of anthracyclines at a functional, structural, and molecular level. I will also use gene silencing and genetic sequencing methods to identify the genetic involvement of cardiotoxicity and the molecular mechanisms of cardiac injury and death. This research will help to provide physicians with the knowledge to personalize chemotherapeutic treatments and better manage cancer survivors who are at an increased risk of cardiotoxicity and cardiovascular mortality. Additionally, the identification of the mechanisms of cardiotoxicity will help basic scientists gain insight into the disease and develop targeted therapies, which will allow for an improvement in patient outcomes and the potential for reducing the global health burden of heart failure.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
411280
Name
Parmar Neha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The effect of gene knockdown in anthracycline induced cardiotoxicity in human induced pluripotent stem cell derived cardiomyocytes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anthracycline; Cancer; Cardiotoxicity; Chemotherapy; Gene Knockdown; Genetics; Genome Biology; Heart Failure; Human Induced Pluripotent Stem Cells; Precision Medicine
Abstract
Anthracyclines, a chemotherapeutic agent, play an important role in improving the survival rates of a wide range of childhood cancers. Despite the importance of anthracyclines in cancer treatments, their use is complicated by the development of heart-related toxicities (known as cardiotoxicities) that have the potential of resulting in heart failure. While there are a variety of known risk factors (e.g. age of diagnosis and dose of drug) implicated in anthracycline-induced cardiotoxicity, it is difficult to accurately determine who is most at risk. Therefore there is a major need to better predict and identify the patients at the highest risk for cardiotoxicity. Recently, variations in genes have been explored as more accurate predictors of a susceptibility to cardiotoxicity. However, there is a limited understanding of how these genetic variations affect cardiomyocytes, primary cells of the heart. In order to address this, I will model cardiotoxicity using human stem cell-derived cardiomyocytes in order to study the effect of anthracyclines at a functional, structural, and molecular level. I will also use gene silencing and genetic sequencing methods to identify the genetic involvement of cardiotoxicity and the molecular mechanisms of cardiac injury and death. This research will help to provide physicians with the knowledge to personalize chemotherapeutic treatments and better manage cancer survivors who are at an increased risk of cardiotoxicity and cardiovascular mortality. Additionally, the identification of the mechanisms of cardiotoxicity will help basic scientists gain insight into the disease and develop targeted therapies, which will allow for an improvement in patient outcomes and the potential for reducing the global health burden of heart failure.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Parmar, Neha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~